Loxo chief Josh Bilenker steps in (temporarily) to head oncology R&D at Eli Lilly as Levi Garraway steps out
Josh Bilenker didn’t just gain a personal windfall by selling Loxo to Eli Lilly for $8.1 billion. He got a new, if temporary, job out of the deal as well.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.